HIK — Hikma Pharmaceuticals Share Price
Last trade - 00:00- £4.47bn
- £5.31bn
- $2.88bn
- 88
- 49
- 97
- 94
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.6 | ||
| PEG Ratio (f) | 1.71 | ||
| EPS Growth (f) | 6.6% | ||
| Dividend Yield (f) | 3.21% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.39 | ||
| Price to Tang. Book | 4.58 | ||
| Price to Free Cashflow | 14.39 | ||
| Price to Sales | 1.81 | ||
| EV to EBITDA | 10.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.86% | ||
| Return on Equity | 12.74% | ||
| Operating Margin | 14.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,203 | 2,341 | 2,553 | 2,517 | 2,875 | 3,085.01 | 3,221.91 | 6.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.41 | -30.77 | +11.04 | +22.29 | +8.93 | -1.34 | +6.6 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
Directors
- Said Darwazah CHM (63)
- Sigurdur Olafsson CEO (52)
- Mazen Darwazah VCH (63)
- Khalid Nabilsi CFO
- Brian Hoffman CEX
- Riad Mishlawi CEX
- Bassam Wael Rushdi Kanaan EVP (56)
- Majda Labadi EVP
- Henriette Nielsen EVP
- Susan Ringdal EVP
- Shahin Fesharaki CSO
- Hussein Arkhagha OTH
- Peter Speirs SEC
- Ali Al-Husry NED (63)
- Patrick Butler NID (60)
- John Castellani NID (70)
- Nina Henderson NID (70)
- Douglas Hurt NID (64)
- Pamela Kirby NID (68)
- Cynthia Schwalm NID (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 8th, 2005
- Public Since
- November 1st, 2005
- No. of Employees
- 8,967
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 221,081,371
- Address
- 1 New Burlington Place, LONDON, W1S 2HR
- Web
- https://www.hikma.com/
- Phone
- +44 2073992760
- Auditors
- PricewaterhouseCoopers LLP
Latest News for HIK
Upcoming Events for HIK
Full Year 2024 Hikma Pharmaceuticals PLC Earnings Release
Hikma Pharmaceuticals PLC Annual Shareholders Meeting
Similar to HIK
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 20:06 UTC, shares in Hikma Pharmaceuticals are trading at 2,022.00p. This share price information is delayed by 15 minutes.
Shares in Hikma Pharmaceuticals last closed at 2,022.00p and the price had moved by +6.25% over the past 365 days. In terms of relative price strength the Hikma Pharmaceuticals share price has underperformed the FTSE All Share Index by -1.12% over the past year.
The overall consensus recommendation for Hikma Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Hikma Pharmaceuticals dividend yield is 3.16% based on the trailing twelve month period.
Last year, Hikma Pharmaceuticals paid a total dividend of $0.78, and it currently has a trailing dividend yield of 3.16%. We do not have any data on when Hikma Pharmaceuticals is to next pay dividends.
We do not have data on when Hikma Pharmaceuticals is to next pay dividends. The historic dividend yield on Hikma Pharmaceuticals shares is currently 3.16%.
To buy shares in Hikma Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2,022.00p, shares in Hikma Pharmaceuticals had a market capitalisation of £4.47bn.
Here are the trading details for Hikma Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HIK
Based on an overall assessment of its quality, value and momentum Hikma Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hikma Pharmaceuticals is 2,345.13p. That is 15.98% above the last closing price of 2,022.00p.
Analysts covering Hikma Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $2.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hikma Pharmaceuticals. Over the past six months, its share price has outperformed the FTSE All Share Index by +10.41%.
As of the last closing price of 2,022.00p, shares in Hikma Pharmaceuticals were trading +5.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hikma Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 10.6. The shares last closed at 2,022.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hikma Pharmaceuticals' management team is headed by:
- Said Darwazah - CHM
- Sigurdur Olafsson - CEO
- Mazen Darwazah - VCH
- Khalid Nabilsi - CFO
- Brian Hoffman - CEX
- Riad Mishlawi - CEX
- Bassam Wael Rushdi Kanaan - EVP
- Majda Labadi - EVP
- Henriette Nielsen - EVP
- Susan Ringdal - EVP
- Shahin Fesharaki - CSO
- Hussein Arkhagha - OTH
- Peter Speirs - SEC
- Ali Al-Husry - NED
- Patrick Butler - NID
- John Castellani - NID
- Nina Henderson - NID
- Douglas Hurt - NID
- Pamela Kirby - NID
- Cynthia Schwalm - NID